Sort   by:  
 Page size 
GenomicsRNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
PRJNA515518 | ENA
GenomicsBeyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma [Methylation]
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma [Methylation]
PRJNA1237270 | ENA
GenomicsBeyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma [RNA-Seq]
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma [RNA-Seq]
PRJNA1237271 | ENA
TranscriptomicsRNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib
ORGANISM(S): Mus musculus 
2020-04-10 | GSE125206 | GEO
GenomicsBRCA-deficient mouse mammary tumor organoids
BRCA-deficient mouse mammary tumor organoids - a tool to study cancer drug resistance
PRJEB22990 | ENA
UnknownSimultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Not available
S-EPMC6082171 | biostudies-literature
UnknownThe function of RAD52 N-terminal domain is essential for viability of BRCA-deficient cells.
Not available
S-EPMC7736796 | biostudies-literature
UnknownNovel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.
Not available
S-EPMC7560981 | biostudies-literature
Methylation profilingBeyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma [Methylation]
Homologous recombination DNA repair deficient (HRD) tumors account for about 50% of tubo-ovarian high-grade serous carcinomas (HGSC) and are associated with a high response to platinum-based chemotherapy. However, a subset of patients with HRD tumors have unexpected resistance to chemotherapy and ex...
ORGANISM(S): Homo sapiens 
2026-01-26 | GSE292140 | GEO
UnknownPCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Not available
S-EPMC7572766 | biostudies-literature
Sort   by:  
 Page size